CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

NCT07397832 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG: Chidamide
DRUG: Rituximab
DRUG: Polatuzumab Vedotin
DRUG: Chidamide Maintenance

Sponsor

Tianjin Medical University Cancer Institute and Hospital